Calcitonin gene-related peptide receptor antagonists (CGRP-RAs), such as rimegepant and ubrogepant, show promise in migraine treatment. Recent advancements include improved bioavailability and fewer side effects. Cutting-edge methods such as monoclonal antibodies enhance targeting precision. This technology's growth is driven by increased migraine prevalence and patient demand for non-opioid options, revolutionizing chronic pain management.
Frequently Asked Questions
The market is segmented based on Global Calcitonin Gene-Related Peptide Receptor Antagonist Market Segmentation, By Drug Type (Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, and Others), Application (Migraine, Osteoarthritis, and Others), Dosage (Tablet and Others), Route of Administration (Oral, Sublingual, and Other), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Calcitonin Gene Related Peptide Receptor Antagonist Market size was valued at USD 3.06 USD Billion in 2023.
The Global Calcitonin Gene Related Peptide Receptor Antagonist Market is projected to grow at a CAGR of 10.73% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
